Core Insights - The company has established a strategic partnership with N Health and Bangkok Dusit Medical Services (BDMS) to introduce advanced microRNA cancer screening solutions in Thailand, marking a significant step forward in early cancer detection and patient outcomes in the region [1][2] Market Overview - The Thai health check market is experiencing substantial growth, projected to reach approximately $500 million by 2030, with a compound annual growth rate (CAGR) of 9.2% starting from 2025. The specialty health check segment is the fastest-growing part, indicating strong demand for advanced and targeted screening solutions [1] Strategic Partnership - The partnership will leverage the company's cutting-edge miRNA technology and innovative screening solutions, such as GASTROClear™ for gastric cancer and LUNGClear™ for lung cancer, to enhance early disease detection services across nearly 60 hospitals within the N Health network [2] Product Launch - The company plans to launch new home screening test kits, HELICORapid for H. pylori detection and FITRapid for fecal occult blood detection, in Thailand starting January 9, 2026, following approvals from the Thai FDA [3] Innovation in Testing - The new home test kits are the first of their kind in the Thai market, featuring an innovative single-device design that integrates sample collection and testing into one component, significantly reducing contamination and user error risks [3][4] Accessibility and Consumer Focus - The company aims to distribute these test kits through modern trade channels and pharmacies across Thailand, aligning with evolving consumer healthcare behaviors and the increasing demand for preventive, self-diagnostic solutions [4]
MIRXES-B(02629)与N Health 建立战略伙伴关系及HELICORapid、F...